ClinicalTrials.gg
RecruitingNCT04893174Updated Dec 4, 2023

Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).

A Phase 1 interventional study of UMC119-06-05 and Hyaluronic acid in Osteoarthritis, Knee, sponsored by Meridigen Biotech Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Meridigen Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 89 studies in Osteoarthritis, Knee with a site in Taiwan — 12 open to participants now, 14 under way, 3 of them phase 3. Osteoarthritis, Knee · Taiwan.

Planned enrollment
81st of 83
6 · median 60
Started
2022
with 2 others
Phase 1
5 of 89
1 open now
Primary completion
2024-09
later than 1 of 13 live
Registered
60th of 89
by date

Among the 89 studies in Osteoarthritis, Knee with a site in Taiwan, this one is the 81st largest by planned enrollment of the 83 interventional ones that give a count, is one of 3 that started in 2022, is one of 5 in phase 1, reaches primary completion later than 1 of the 13 other live ones, and was the 60th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 89 studies in Osteoarthritis, Knee with a site in Taiwan are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Osteoarthritis, Knee with a site in Taiwan, or all of them as a file.
02

Study summary

The clinical study with UMC119-06-05 is designed to investigate the safety in patients with mild to moderate knee osteoarthritis (KOA). This will be a dose escalation, open label, single-center study in adult with mild to moderate knee osteoarthritis. UMC119-06-05 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of knee osteoarthritis.

Read the detailed description

Knee osteoarthritis (KOA), also known as degenerative joint disease, is the most common type of arthritis diagnosed. KOA is typically the result of wear and tear and progressive loss of articular cartilage. The prevalence of the Knee osteoarthritis will continue to increase as life expectancy and obesity rises. Osteoarthritis is typically a progressive disease that may eventually lead to disability. The intensity of the clinical symptoms may vary from each individual. However, they typically become more severe, more frequent, and more debilitating over time.The intensity of the clinical symptoms may vary from each individual. However, they typically become more severe, more frequent, and more debilitating over time.

The rate of progression also varies for each individual. Common clinical symptoms include knee pain that is gradual in onset and worse with activity, knee stiffness and swelling, pain after prolonged sitting or resting, and pain that worsens over time. Treatment for knee osteoarthritis begins with conservative methods and progresses to surgical treatment options when conservative treatment fails. While medications can help slow the progression of RA and other inflammatory conditions, no proven disease-modifying agents for the treatment of knee osteoarthritis currently exist. Among the more innovative, experimental therapies, mesenchymal stromal cells (MSCs) are proposed as a novel therapy with potential in treatment of KOA.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • KOA
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ambulatory subjects with osteoarthritis of the knee with symptoms for at least 3 months, that may be taking conservative therapy (e.g. oral anti-inflammatory medication), and/or undergoing physical therapy. In subjects with bilateral knee osteoarthritis, the more symptomatic knee will be the target knee.
  2. Subjects of age between ≥40 through ≦ 90 years.
  3. Subject diagnosed with knee osteoarthritis of grade II and III according to the Kellgren-Lawrence Grading Scale on the target knee.
  4. Subject with joint pain equal or greater than 7 (total pain score 24 point) on the target knee assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
  5. Subject or legal guardian is willing to provide written to participate in the study after reading the informed consent form and the information provided, and has had the opportunity to discuss the study with the investigator or designee.
  6. Women of should have a negative urine pregnancy test prior to administration of product, and the subject must agree within at least 4 weeks after the study administration to use a double barrier method of .UNLESS they meet the following criteria:(1) : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40mIU/mL, OR; (2) 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy.
  7. If a male and heterosexually active with a female of childbearing potential, the subject must agree within at least 4 weeks after the study administration to use a double barrier method of birth control (or must have been surgically sterilized) and to not donate sperm.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with (BMI) over 40.
  2. Subjects with knee deformity (knee varus or valgus greater than 10 degrees) on the target knee.
  3. Subjects with acute inflammation or tense effusion (e.g., infection), or bleeding on the target knee as judged by principal investigator (PI).
  4. Subjects with ligament instability (cruciate ligaments or collateral ligaments) or ligament laxity of the target knee as judged by PI.
  5. Subjects with a history of surgery of articular injury, ligament reconstruction and meniscus repair on the target knee joint within previous 6 months.
  6. Subjects with history of arthroscopic surgery in the target knee in the past 6 months or planned to have arthroscopy surgery during the trial period (e.g., scheduled for/awaiting arthroscopy or a knee replacement procedure)
  7. Subjects with history of knee replacement procedure on the target knee.
  8. Subjects with intra-articular infiltration of any treatments on the target knee (such as hyaluronic acid, or rich plasma (PRP)) in the last 3 months prior to study inclusion.
  9. Subjects with known history of osteoarthritis of hip or ankle.
  10. Subjects with known history of any systemic rheumatic disease including but not limited to: Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lymphoma, arthritis associated with inflammatory bowel disease, sarcoidosis or amyloidosis.
  11. Subjects with Rheumatoid Factor levels (>15.9 IU/mL) in laboratory tests.
  12. Subjects with joint diseases (except knee osteoarthritis) or infectious arthritis on the target knee considered by investigator not eligible to enter the study.
  13. Subjects who are known to be infected with .
  14. Subjects with active or active .
  15. Subjects who have a significant concomitant illness as judged by principal investigator (PI) including, but not limited to:

    1. Severe renal insufficiency ( \< 30 mL/min/1.73 m2); or
    2. hepatic (e.g. Class C); or
    3. Severe congestive heart failure ( class 3 and 4); or
    4. Severe pulmonary dysfunction, including severe (COPD) and history of lung resection; or
    5. Any type of ; or
    6. Uncontrolled Diabetes Mellitus ( > 10%)
  16. Subjects with uncorrected hematology test including, but not limited to:

    1. \< 8 g/dl; or
    2. White blood cell count \< 3,000/mm3; or
    3. (INR) of Coagulopathy >1.5; or
    4. Platelet count \< 80,000/mm3
  17. Subjects who have the following conditions in laboratory tests:

    1. >2 × for (ALT) or aspartate aminotransferase (AST) ; or
    2. Total > 1.5 mg/dl
  18. Subjects with known history of allergy or to any component of product, including dimethyl sulfoxide, cell therapies, or hyaluronic acid.
  19. Subjects with known history of allergy or hypersensitivity to any concomitant medications, or rescue medications.
  20. Subjects who have a significant skin disease at the injection site on target knee as judged by principal investigator (PI).
  21. Subjects who are pregnant (or planning to become pregnant within 2 years of investigational product treatment) or lactating.
  22. Participation in another clinical trial or treatment (e.g., therapies, systemic steroids, cytotoxic drugs, chemotherapy, radiation therapy, new investigational drugs or cell therapy) within 3 months prior to inclusion in the study.
  23. to MRI:

    • Indwelling medical devices such as pacemakers, aneurysm clip, etc.
    • Indwelling metal from any other cause (trauma, etc.). To be excluded with history and/or radiographs, as necessary
  24. Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    UMC119-06-05

    Human Umbilical Cord Derived-Mesenchymal Stem Cells. Subjects will receive a single-dose intra-articular (IA) injection of UMC119-06-05 followed by an IA injection of hyaluronic acid.

    Biological: UMC119-06-05 · Device: Hyaluronic acid

Interventions

  • BiologicalUMC119-06-05

    Subjects will receive a single-dose IA injection of UMC119-06-05 followed by an IA injection of hyaluronic acid. Cohort 1: Low does UMC119-06-05 Cohort 2: High does UMC119-06-05

  • DeviceHyaluronic acid

    IA injection of hyaluronic acid.

06

What researchers measure

Primary outcomes

  1. The incidence and frequency of adverse events related to administration of UMC119-06-05.

    Incidence of Treatment-Emergent Adverse Events (TEAEs). Incidence of withdrawals due to Adverse Events(AEs).

    Time frame: 1 months from the day of administration

Secondary outcomes

  1. Changes of total score in the Western Ontario and McMaster (WOMAC) assessment on the target knee.

    Improvement in total score (pain subscale, and stiffness subscale, and physical function subscale) as assessed by mean change in WOMAC index.

    Time frame: from baseline up to 52 weeks after administration

  2. Changes of arthritis pain on target knee using the 100-mm visual-analogue scale (VAS).

    VAS scale range 0 to 100 mm, with higher scores indicates greater pain intensity. A decrease in score represents a decrease in disease related pain of knee.

    Time frame: from baseline up to 52 weeks after administration

  3. Whole Organ Magnetic Resonance Imaging Score (WORMS).

    Changes on the target knee for knee cartilage and the joint soft tissues assessed by Whole Organ Magnetic Resonance Imaging Score (WORMS) using magnetic resonance imaging (MRI) of T2 mapping.

    Time frame: from baseline up to 52 weeks after administration

  4. Changes in Kellgren-Lawrence (K-L) grading and joint space on target knee.

    The severity of knee OA was defined as kellgren-lawrence (K-L) classification criteria. Changes from baseline to post-treatment visits on the target knee for Kellgren-Lawrence (K-L) grading and joint space in X-ray examination results.

    Time frame: from baseline up to 52 weeks after administration

  5. Amount of rescue medications required.

    Total amount of acetaminophen or non-steroidal anti-inflammatory drugs (NSAID)

    Time frame: at first 4 weeks, first 28 weeks and the whole study period.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 24 months after the start.

Of 34 industry-sponsored phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 21. This study's planned 24 months is above that.

Counting every sponsor, half of 61 studies reached it within 20 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2021
First posted
May 19, 2021
StartActual
Sep 15, 2022
Primary completionEst.
Sep 2024
CompletionEst.
Jun 2025
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04893174
Lead sponsor
Meridigen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Sep 15, 2022
Primary completion
Sep 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Dec 4, 2023

Study contacts

Claire Liao, MS
Contact
claire.liao@meridigen.com
+886-2-8978-7777 ext. 19965
Joseph Chen, MS
Contact
joseph.chen@meridigen.com
+886-2-8978-7777 ext. 19905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion